Roivant Sciences (ROIV) Net Income (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Net Income came in at $373.2 million in Q4 2024, up 264.66% YoY from $102.3 million in Q1 2024, and up 966.2% on a QoQ basis from -$43.1 million in Q3 2024.
Roivant Sciences (ROIV) Net Income (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Net Income data on file, last reported at $373.2 million in Q4 2024.
- Quarterly Net Income rose 264.66% year-over-year to $373.2 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $373.2 million (up 306.6% YoY) and the FY2025 annual result came in at $373.2 million, up 218.42% from the prior year.
- Net Income grew to $373.2 million in Q4 2024, from -$43.1 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $373.2 million in Q4 2024 to a low of -$1.1 billion in Q4 2022.
- A 5-year average of -$216.2 million and a median of -$225.6 million in 2021 frame the typical range for Net Income.
- Annual changes were most pronounced in 2021 — Net Income tumbled 1167.12% — and 2024, when it surged 264.66%.
- Tracing ROIV's Net Income over 5 years: stood at -$275.6 million in 2020, then slumped by 129.61% to -$632.8 million in 2021, then tumbled by 66.66% to -$1.1 billion in 2022, then surged by 78.51% to -$226.6 million in 2023, then surged by 264.66% to $373.2 million in 2024.
- The last three Net Income figures came in at $373.2 million (Q4 2024), -$43.1 million (Q3 2024), and $89.1 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -290.61 Mn |
| Dec 31, 2024 | 373.19 Mn |
| Sep 30, 2024 | -43.08 Mn |
| Jun 30, 2024 | 89.09 Mn |
| Dec 31, 2023 | -226.64 Mn |
| Sep 30, 2023 | -86.10 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -632.80 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |